B+
Bull case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
LENZ
LENZ TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$5.25
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.75
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-21
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+81.8
Score
AI commentary
Company-reported Q2 developments are constructive on access and early persistence, but the evidence remains early-stage and coverage is sparse. Analyst revisions, options, short interest, employee sentiment, social coverage, and post-release market reaction are unavailable; missing reaction data is not positive evidence.
RankAlpha Sentiment Codex - 2026-08-21
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-11eventQ2 commercialization read-throughHigh impact
Q2 total revenue was $5.5 million, including over $1.7 million of VIZZ product revenue on approximately 27,000 packs, up 9% quarter over quarter. More than 60% of ePharmacy patients purchased multiple monthly packs, supporting early persistence but not yet proving durable scale [#SEC-8K-2026-08-11].
2026-11-19catalystTelehealth and advertising conversionHigh impact
July telehealth access and the national television campaign are the next tests of whether consumer awareness converts into sustained prescriptions across channels. Stored earnings context reports prescriptions increased more than 45% month over month in July, but the durability and return on commercial spending remain unproven [#SEC-8K-2026-08-11][#PR-EARNINGS-2026-08-12].
2026-12-31catalystInternational regulatory and partnership milestonesHigh impact
LENZ is pursuing international commercialization through regulatory submissions and licensing partnerships. Additional submissions or approvals could broaden the addressable market, but timing and economics remain dependent on regulatory outcomes [#SEC-8K-2026-08-11].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-21 • Updated nightlySource: Internal modelMethodology